Invicro Acquires Imanova to Expand Global Imaging Capabilities

Invicro and Imanova will merge all activities to establish the world’s largest provider of translational imaging services and analytics from pre-clinical development through to late-phase clinical trials.

Invicro focuses on improving the role and function of imaging in translational drug discovery and development across all therapeutic areas. The company provides a full range of image informatics, engineering and operational services. Through its preclinical and clinical divisions, Invicro develops and leverages the latest approaches in imaging quantitative biomarkers.

Imanova, an alliance between the UK's Medical Research Council, Imperial College London, King's College London and University College London, acts as a conduit between academia and industry. Imanova is among the leading players in the application of PET and MR imaging, with a focus on translational research to support the transition from pre-clinical studies to Phase I/II studies in humans. The services of the combined business cover the entire translational spectrum, ranging from novel biomarker evaluation and development in early discovery to late-phase clinical trials support.

The addition of Imanova is part of Invicro’s ongoing growth strategy to realize its mission to improve therapeutic discovery and development efforts through visualizing and quantifying biological and pathological processes in order to better diagnose, characterize, prevent, treat and, ultimately, cure disease.

“Joining forces with the phenomenal research team at Imanova expands our translational, analytic and geographic offering. Our groups share a common mission of improving research trials through the development and application of quantitative imaging biomarkers,” said Dr. Jack Hoppin, Invicro’s Co-Founder and CEO. “Our combined research teams hold a collective pride in the development of novel offerings in discovery as well as the engineering of scalable, reproducible solutions for deployment in late-phase development.”

“Invicro develops innovative analytical approaches for clinical trials, which are highly complementary with our own. Combining Invicro’s and Imanova’s analytics platforms means we have a best-in-class imaging informatics team to help reduce risk in drug development,” said Dr. Kevin Cox, Imanova’s CEO. “As a combined enterprise we will be a truly translational quantitative biomarker company, with an expanding late-phase clinical trial offering, able to meet the needs of a growing global market.”

Related Links:
Invicro
Imanova